Omvoh Side Effects

Generic name: mirikizumab

Medically reviewed by Drugs.com. Last updated on Jan 23, 2024.

Note: This document contains side effect information about mirikizumab. Some dosage forms listed on this page may not apply to the brand name Omvoh.

Applies to mirikizumab: solution.

Serious side effects of Omvoh

Along with its needed effects, mirikizumab (the active ingredient contained in Omvoh) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking mirikizumab:

More common

Body aches or pain
chills
cough
diarrhea
ear congestion
fever
headache
loss of taste or smell
loss of voice
muscle pain
nausea or vomiting
sneezing
sore throat
stuffy or runny nose
trouble breathing
unusual tiredness or weakness

Less common

Burning or stinging of the skin
painful blisters on the trunk of body
painful cold sores or blisters on the lips, nose, eyes, or genitals

Incidence not known

Chest tightness
dark urine
difficulty swallowing
fast heartbeat
hives, itching, skin rash
loss of appetite
lower back or side pain
painful or difficult urination
puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
stomach pain, severe
yellow eyes or skin

Other side effects of Omvoh

Some side effects of mirikizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site

Less common

Difficulty in moving
joint pain
muscle pain or stiffness

For Healthcare Professionals

Applies to mirikizumab: intravenous solution, subcutaneous solution.

General

The most common adverse reactions reported are upper respiratory tract infection, headache, rash, and injection site reactions.^[Ref]

Cardiovascular

Common (1% to 10%): Hypertension^[Ref]

Dermatologic

Common (1% to 10%): Rash^[Ref]

Rash included macular rash, maculopapular rash, pruritic rash, and popular rash.^[Ref]

Gastrointestinal

Common (1% to 10%): Ulcerative colitis, abdominal pain, diarrhea, gastroesophageal reflux disease

Frequency not reported: Intestinal sepsis^[Ref]

Hematologic

Common (1% to 10%): Anemia^[Ref]

Hepatic

Uncommon (0.1% to 1%): Increased AST, increased ALT^[Ref]

Immunologic

Very common (10% or more): Anti-drug antibodies (up to 23%)^[Ref]

Local

Common (1% to 10%): Injection site reactions^[Ref]

Injection site reactions included erythema, hypersensitivity, pain, reaction, and urticaria at the injection site.^[Ref]

Musculoskeletal

Common (1% to 10%): Arthralgia^[Ref]

Other

Common (1% to 10%): Herpes viral infection, pyrexia, increased blood creatine phosphokinase, fatigue

Frequency not reported: Listeria sepsis^[Ref]

Herpes viral infection included herpes zoster, herpes simplex, and oral herpes.^[Ref]

Nervous system

Common (1% to 10%): Headache^[Ref]

Respiratory

Very common (10% or more): Upper respiratory tract infections (up to 14%)

Frequency not reported: Pneumonia^[Ref]

Upper respiratory tract infections included COVID-19, nasopharyngitis, pharyngitis, rhinitis, oropharyngeal discomfort, oropharyngeal pain, tonsillitis, viral upper respiratory tract infection, acute sinusitis, and sinusitis.^[Ref]